neuroendocrine%20tumors
NEUROENDOCRINE TUMORS
Neuroendocrine tumors are rare, small, slow-growing epithelial neoplasms with predominant neuroendocrine differentiation found in most organs of the body.
They arise from cells throughout the diffuse endocrine system.
Carcinoid tumors and pancreatic neuroendocrine tumors are the most common.
Carcinoid tumors arise from the lungs & bronchi, stomach, small intestine, appendix, rectum or thymus.
Majority of the neuroendocrine tumors are sporadic but some tumors are caused by inherited genetic syndromes such as multiple endocrine neoplasia, Von-Hippel Lindau disease, tuberous sclerosis complex and neurofibromatosis.
They have the ability to store and secrete various peptides and neuroamines.

Follow Up

  • NETs are slow growing but they may progress faster if they are poorly differentiated or have a high Ki67 index > 5%
  • Patients should be monitored more closely during the first year after diagnosis to determine the status of the disease
    • Assess clinical manifestations, biomarkers, presence of new sites of disease, & quality of life during treatment
    • Routine evaluations, such as echocardiogram for patients w/ elevated 5-HIAA, to detect carcinoid heart disease in its early stages can improve prognosis
  • PET scan & somatostatin scintigraphy are not advised for routine surveillance
  • It is recommended to have re-evaluation of the patient 3-12 months after surgical resection or earlier if the patient is symptomatic
    • >1 year following surgical resection, every 6-12 months is recommended schedule for follow-up
    • Abdominal or pelvic multiphasic CT or MRI, gastrin, CgA & 5-HIAA levels may be used for disease monitoring
  • Low-risk patients (eg carcinoid tumor of the appendix) usually require no follow-ups
    • Low-risk patients are those having <2 cm primary tumor (<1 cm for rectal tumors), no nodal involvement & have low Ki67 < 5%
  • Repeat rectal MRI or endoscopic ultrasound 6-12 months after initial treatment is recommended for rectal NETs 1-2 cm in size & for gastric NETs type 1 or 2 for the 1st 3 months then annually if negative for pathologies
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

12 Apr 2017
Patients with fibromyalgia syndrome (FMS) are at an increased risk of peptic ulcer disease (PUD), a new study shows.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.
01 Jun 2015
A mixture of the flavonoids diosmin, troxerutin, and hesperidin is safe and effective for the symptomatic management of patients with acute haemorrhoidal disease, a prospective, randomised, triple-blind, controlled trial revealed.